Lista de obras -

1054Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age.

artículo científico publicado en 2014

1204. Increased Risk of Respiratory Infections Among Healthcare Personnel (HCP) Caring for Children

1205. Healthcare Personnel Knowledge, Attitudes, and Beliefs Towards Infection Prevention and Control Measures for Protection from Respiratory Infections

artículo científico publicado en 2019

1716. Results of the Respiratory Protection Effectiveness Clinical Trial (ResPECT)

410. Influence of Pre-season Antibody Titers to Influenza on Influenza Risk in a Cohort of Healthcare Personnel

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

artículo científico publicado en 1999

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

scientific article published on 01 February 1996

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

artículo científico publicado en 1998

Anaerobic endocarditis caused by Staphylococcus saccharolyticus

artículo científico publicado en 1990

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

artículo científico publicado en 1998

Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses

artículo científico publicado en 2020

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

artículo científico publicado en 1996

Association of malnutrition with nosocomial infection

artículo científico publicado en 1989

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1993

Bacterial meningitis in the elderly

scientific article published on 01 August 1984

Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection

artículo científico publicado en 2004

CNS infection and bacteremia due to clostridium septicum

artículo científico publicado en 1984

Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.

artículo científico publicado en 2001

Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.

artículo científico publicado en 2006

Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network

artículo científico publicado en 1990

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

artículo científico publicado en 2004

Comparison of the immune response to recombinant gp120 in humans and chimpanzees

artículo científico publicado en 1994

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

artículo científico publicado en 2008

Coronavirus and Other Respiratory Illnesses Comparing Older with Young Adults

artículo científico

Current progress in HIV vaccines

artículo científico publicado el 1 de noviembre de 1991

Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

artículo científico publicado en 2001

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

artículo científico publicado en 1998

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults

artículo científico publicado en 2012

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Networ

artículo científico publicado en 1992

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1994

Effect of antineoplastic agents on gamma-interferon production in human peripheral blood mononuclear cells

scientific article published on 01 November 1984

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

artículo científico publicado en 1999

Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study

artículo científico publicado en 2003

Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses.

artículo científico publicado en 2017

Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses

artículo científico publicado en 1991

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults

artículo científico publicado en 1990

Genetic and Immunologic Characterization of Viruses Infecting MN‐rgp120‐Vaccinated Volunteers ⬇️

artículo científico publicado el 1 de agosto de 1997

HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.

artículo científico publicado en 2001

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1994

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network

scientific article published on 01 February 1995

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

artículo científico publicado en 1999

Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.

artículo científico publicado en 2009

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

artículo científico publicado en 1998

Immunity to influenza in older adults with chronic obstructive pulmonary disease

artículo científico publicado en 2004

Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women

artículo científico publicado en 1999

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

artículo científico publicado en 1996

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial

artículo científico

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial

artículo científico publicado en 2006

Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination

artículo científico publicado en 2006

Impact of mandatory vaccination of healthcare personnel on rates of influenza and other viral respiratory pathogens

artículo científico

Impact of removing gentamicin from an antibiotic restriction program

artículo científico publicado en 1985

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine

artículo científico publicado en 1995

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

scientific article published on 01 July 1993

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

artículo científico publicado en 1998

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly

artículo científico publicado en 1996

Infection Control Practices in Gastrointestinal Endoscopy in the United States: A National Survey

artículo científico publicado el 1 de mayo de 1991

Influence of preseason antibodies against influenza virus on risk of influenza infection among healthcare personnel

journal article published in 2022

Influenza Virus Vaccination of Patients With Chronic Lung Disease ⬇️

artículo científico publicado el 5 de noviembre de 1997

Interpatient mutational spectrum of human coronavirus-OC43 revealed by illumina sequencing.

artículo científico publicado en 2017

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

artículo científico

Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines

artículo científico publicado en 1988

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado el 1 de enero de 1992

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group

artículo científico publicado en 1999

Male genital tuberculosis: a review of the literature with instructive case reports

artículo científico publicado en 1985

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

scientific article published on 01 March 1998

N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial

artículo científico publicado en 2019

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

scientific article published on 01 August 1994

Nontuberculous mycobacterial disease. Experience in a southern California hospital

artículo científico publicado el 1 de febrero de 1983

Outpatient healthcare personnel knowledge and attitudes towards infection prevention measures for protection from respiratory infections

artículo científico

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

artículo científico publicado en 2014

Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in Serum ⬇️

artículo científico publicado el 13 de octubre de 2010

Protecting healthcare personnel in outpatient settings: the influence of mandatory versus nonmandatory influenza vaccination policies on workplace absenteeism during multiple respiratory virus seasons

artículo científico publicado en 2018

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

article

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older

artículo científico

Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine

artículo científico publicado en 2003

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1995

Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.

artículo científico publicado en 2004

Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7"

scientific article published on 27 August 2007

Risk factors for healthcare personnel infection with endemic coronaviruses (HKU1, OC43, NL63, 229E): results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT)

artículo científico publicado en 2020

Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group ⬇️

artículo científico publicado el 20 de septiembre de 1997

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

artículo científico publicado en 2001

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

artículo científico publicado en 1996

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

artículo científico publicado en 1993

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

artículo científico publicado en 2002

Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults

artículo científico publicado en 2015

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults

artículo científico publicado en 2007

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

artículo científico publicado en 2013

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

artículo científico publicado en 2001

Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases

artículo científico publicado en 1986

Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group

artículo científico publicado en 1996

Specific activation strategies for amplification of low CTL signals

artículo científico publicado el 1 de agosto de 1992

Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults

artículo científico publicado en 1991

Take-home kits to detect respiratory viruses among healthcare personnel: lessons learned from a cluster randomized clinical trial

artículo científico

The Influence of Mandatory Vs. Non-Mandatory Influenza Vaccination Policies on Workplace Absenteeism During Respiratory Virus Season.

artículo científico publicado en 2017

The Respiratory Protection Effectiveness Clinical Trial (ResPECT): a cluster-randomized comparison of respirator and medical mask effectiveness against respiratory infections in healthcare personnel

artículo científico publicado en 2016

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1991

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

artículo científico publicado el 1 de agosto de 1992

Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network

artículo científico publicado en 1994

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies

artículo científico publicado en 1999

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines

artículo científico publicado en 1997

Lista de obras de

1054Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age.

1204. Increased Risk of Respiratory Infections Among Healthcare Personnel (HCP) Caring for Children

1205. Healthcare Personnel Knowledge, Attitudes, and Beliefs Towards Infection Prevention and Control Measures for Protection from Respiratory Infections

1716. Results of the Respiratory Protection Effectiveness Clinical Trial (ResPECT)

410. Influence of Pre-season Antibody Titers to Influenza on Influenza Risk in a Cohort of Healthcare Personnel

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Anaerobic endocarditis caused by Staphylococcus saccharolyticus

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Association of malnutrition with nosocomial infection

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

Bacterial meningitis in the elderly

Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection

CNS infection and bacteremia due to clostridium septicum

Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.

Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.

Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

Comparison of the immune response to recombinant gp120 in humans and chimpanzees

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

Coronavirus and Other Respiratory Illnesses Comparing Older with Young Adults

Current progress in HIV vaccines

Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Networ

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

Effect of antineoplastic agents on gamma-interferon production in human peripheral blood mononuclear cells

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study

Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses.

Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults

Genetic and Immunologic Characterization of Viruses Infecting MN‐rgp120‐Vaccinated Volunteers ⬇️

HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network

HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

Immunity to influenza in older adults with chronic obstructive pulmonary disease

Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial

Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination

Impact of mandatory vaccination of healthcare personnel on rates of influenza and other viral respiratory pathogens

Impact of removing gentamicin from an antibiotic restriction program

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly

Infection Control Practices in Gastrointestinal Endoscopy in the United States: A National Survey

Influence of preseason antibodies against influenza virus on risk of influenza infection among healthcare personnel

Influenza Virus Vaccination of Patients With Chronic Lung Disease ⬇️

Interpatient mutational spectrum of human coronavirus-OC43 revealed by illumina sequencing.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group

Male genital tuberculosis: a review of the literature with instructive case reports

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

Nontuberculous mycobacterial disease. Experience in a southern California hospital

Outpatient healthcare personnel knowledge and attitudes towards infection prevention measures for protection from respiratory infections

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in Serum ⬇️

Protecting healthcare personnel in outpatient settings: the influence of mandatory versus nonmandatory influenza vaccination policies on workplace absenteeism during multiple respiratory virus seasons

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older

Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network

Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.

Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7"

Risk factors for healthcare personnel infection with endemic coronaviruses (HKU1, OC43, NL63, 229E): results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT)